Clinical trials: Stage I Pancreatic Cancer AJCC v8
Pancreatic Cancer
Identification of Biomarkers for Early Detection of Pancreatic Cancer
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897494
- Testing
- protein expression analysis, laboratory biomarker analysis, mass spectrometry
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Pancreatic Cancer
ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)
To seek preliminary evidence of antitumor activity (progression free survival) of Erlotinib in combination with standard adjuvant chemoradiation and chemotherapy in patients with resected adenocarcinoma of the pancreas.
- Trial name
- NCT00313560
- Testing
- erlotinib hydrochloride
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Neoplasm
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
This phase I trial tests the safety, side effects, and best dose of sunitinib malate in combination with lutetium Lu 177 dotatate in treating patients with pancreatic neuroendocrine tumors.
- Conditions
- Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Neoplasm, Stage III Pancreatic Neuroendocrine Tumor AJCC v8, Stage IV Pancreatic Neuroendocrine Tumor AJCC v8
- Trial name
- NCT05687123
- Testing
- Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate
- Where
- 10 sites in United States, Canada
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
This phase I/II trial tests the effect of pegcetacoplan in combination with oxaliplatin, irinotecan, leucovorin, and fluorouracil (mFOLFIRINOX) in treating patients with pancreatic ductal adenocarcinoma (PDAC) that has spread…
- Trial name
- NCT07214298
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Roswell Park Cancer Institute
Pancreatic Cancer
Combination Chemotherapy Followed by Chemotherapy and Radiation Therapy and/or Surgery in Treating Patients Who Have Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with radiation therapy and/or surgery may kill more tumor cells.
- Trial name
- NCT00003332
- Testing
- cisplatin, gemcitabine hydrochloride, surgical procedure
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- NYU Langone Health
Recurrent Colon Cancer, Extensive Stage Small Cell Lung Cancer
Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
RATIONALE: Vaccines made from mutated ras peptides may make the body build an immune response to and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune…
- Conditions
- Recurrent Colon Cancer, Extensive Stage Small Cell Lung Cancer, Stage III Pancreatic Cancer, Stage III Rectal Cancer
- Trial name
- NCT00019006
- Testing
- Detox-B adjuvant, ras peptide cancer vaccine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma
Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma
This phase I/II trial tests the safety, side effects, best dose and how well giving selumetinib with trastuzumab deruxtecan (DS-8201a) works for the treatment of pancreatic ductal adenocarcinoma that may have spread from where it…
- Conditions
- Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Trial name
- NCT07619521
- Testing
- Biospecimen Collection, Diagnostic Imaging Testing, Echocardiography Test
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Radiation Therapy Plus Chemotherapy in Treating Patients With Pancreatic Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00002689
- Testing
- dexamethasone, fluorouracil, brachytherapy
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Center for Molecular Medicine
Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
This phase II trial evaluates whether early switching from modified fluorouracil/irinotecan/leucovorin/oxaliplatin (mFOLFIRINOX) chemotherapy regimen to a combination of gemcitabine and nab-paclitaxel (GA) before surgery is…
- Conditions
- Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8, Stage I Pancreatic Cancer American Joint Committee on Cancer v8, Stage III Pancreatic Cancer American Joint Committee on Cancer v8
- Trial name
- NCT04539808
- Testing
- Capecitabine, Fluorouracil, Irinotecan Hydrochloride
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- OHSU Knight Cancer Institute
Pancreatic Cancer, Perioperative/Postoperative Complications
Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection
RATIONALE: Drugs such as vapreotide may prevent complications following pancreatic resection. It is not yet known if vapreotide is more effective than no further therapy in preventing side effects of pancreatic resection.
- Trial name
- NCT00014651
- Testing
- vapreotide, conventional surgery
- Where
- 18 sites in United States
- Sponsor
- Mayo Clinic
Pancreatic Cancer
Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00524069
- Testing
- bevacizumab, capecitabine, gemcitabine hydrochloride
- Sponsor
- Roswell Park Cancer Institute
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
This phase II trial studies how well combination chemotherapy before and after surgery works in treating patients with localized pancreatic cancer.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage I Pancreatic Cancer, Stage IIA Pancreatic Cancer
- Trial name
- NCT02047474
- Testing
- oxaliplatin, leucovorin calcium, irinotecan hydrochloride
- Where
- 9 sites in United States
- Volunteers
- 46 people
- Sponsor
- Yale University
Pancreatic Cancer
Genistein in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00882765
- Testing
- genistein
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center